Plain-English translation of NCT03794076 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a nasal spray, as an add-on treatment for schizophrenia. is a medication that has been safely used for over 25 years to treat asthma and allergies, but researchers believe it may also help with schizophrenia symptoms. You would take this medication in addition to your regular antipsychotic medication to see if it reduces your symptoms.
Current schizophrenia medications help many people, but they don't work well enough for everyone and don't reliably improve certain symptoms like difficulty thinking clearly or negative emotions. Researchers used a special computer analysis to search for existing, safe medications that might work better when added to current treatments, and this medication appeared to be a promising candidate.
You likely qualify if…
You likely don't qualify if…
You would receive either the nasal spray medication or a placebo (saline spray) and use it as directed while continuing to take your current antipsychotic medication. The study involves visits with researchers who will monitor your symptoms and overall health throughout the trial. You would be part of the study for several months while the researchers track whether the medication helps reduce your symptoms.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Vishwajit Nimgaonkar, MD PhD
Collaborators
Stanley Medical Research Institute
Enrollment target
~160 participants
Started
April 2019
Primary completion
January 2028
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vishwajit L Nimgaonkar, M.D., Ph.D.
University of Pittsburgh
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.